Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer.
Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.
